Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Association Of Β-Amyloid Level, Clinical Progression And Longitudinal Cognitive Change In Normal Older Individuals, Laura M. Van Der Krall, Thanh Truong, Samantha C. Burnham, Vincent Doré, Rachel S. Mulligan, Svetlana Bozinovski, Fiona Lamb, Pierrick Bourgeat, Jurgen Fripp, Stephanie Schultz, Yen Y. Lim, Simon M. Laws, David Ames, Christopher Fowler, Stephanie R. Rainey-Smith, Ralph N. Martins, Olivier Salvado, Joanne Robertson, Paul Maruff, Colin L. Masters, Victor L. Villemagne, Christopher C. Rowe
Association Of Β-Amyloid Level, Clinical Progression And Longitudinal Cognitive Change In Normal Older Individuals, Laura M. Van Der Krall, Thanh Truong, Samantha C. Burnham, Vincent Doré, Rachel S. Mulligan, Svetlana Bozinovski, Fiona Lamb, Pierrick Bourgeat, Jurgen Fripp, Stephanie Schultz, Yen Y. Lim, Simon M. Laws, David Ames, Christopher Fowler, Stephanie R. Rainey-Smith, Ralph N. Martins, Olivier Salvado, Joanne Robertson, Paul Maruff, Colin L. Masters, Victor L. Villemagne, Christopher C. Rowe
Research outputs 2014 to 2021
Objective To determine the effect of β-amyloid (Aβ) level on progression risk to mild cognitive impairment (MCI) or dementia and longitudinal cognitive change in cognitively normal (CN) older individuals. Methods All CN from the Australian Imaging Biomarkers and Lifestyle study with Aβ PET and ≥ 3 years follow-up were included (n = 534; age 72 ± 6 years; 27% Aβ positive; follow-up 5.3 ± 1.7 years). Aβ level was divided using the standardized 0–100 Centiloid scale: < 15 CL negative, 15–25 CL uncertain, 26–50 CL moderate, 51–100 CL high, > 100 CL very high, noting > 25 CL approximates a positive scan. Cox proportional hazards analysis and linear mixed effect models were used to assess …